As the sound of pile driver at the Edward St. John’s Learning and Teaching Center construction site boomed across Campus Drive, officials broke ground Friday morning on another project: a bioengineering building aimed at forwarding research in a relatively new field.
Britain’s GlaxoSmithKline (GSK.L) has asked its shareholders to vote at a meeting on Dec. 18 on its proposed major deal with Switzerland’s Novartis (NOVN.VX), which will see the two pharmaceutical group trade more than $20 billion of assets.
Digital technologies such as electronic medical records, mobile devices, and analytics offer the potential to transform health care. Whether it’s a patient using her smartphone to better manage her diabetes, a provider monitoring a patient for arrhythmia remotely, or an electronic health-record system alerting a clinician of a potential drug allergy, digital technologies can create meaningful value for patients and practitioners alike. Yet there are significant barriers to the development and adoption of such technologies that academic medical centers are uniquely positioned to overcome.
Myron M. Levine, MD, DTPH, director of the University of Maryland School of Medicine Center for Vaccine Development (CVD), and Dean E. Albert Reece, MD, PhD, MBA, announced today the start of a clinical trial in Baltimore to evaluate different dosage levels of a promising experimental Ebola vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and GlaxoSmithKline (GSK
British drugmaker AstraZeneca is doubling down on Maryland, spending $200 million to expand its Frederick manufacturing facility a year after shifting hundreds of out-of-state jobs to Montgomery County.
There are presently massive shifts occurring in the competitive global landscape of health, and particularly in the life sciences. As we approach 2015, it is imperative that leaders in the health space understand the trends and shifts happening around them, not only in the US, but also in international markets, cities and service lines.
Drug giant AstraZeneca will expand its biologics manufacturing center in Frederick and add hundreds of jobs to its operations there.
The drug giant will spend more than $200 million to increase production capacity. MedImmune, AstraZeneca’s biologics research and development arm, has more than 120 drugs in its research pipeline, including more than 30 in clinical development. AstraZeneca says the expansion will support its research.
Local companies, along with County Executive Leggett, are exploring incredible international business opportunities in the Indian market as part of the County’s business mission to India November 13 through 22. Read the press release to learn more.
Few businesses owned by venture capital firms have been awarded Small Business Innovation Research awards since this program was opened to them two years ago.
Through the SBIR program, 11 federal agencies spend at least 2.8 percent of their outside research budgets with small businesses. Only two of these agencies — the National Institutes of Health and the Advanced Research Projects Agency-Energy — have allowed VC-owned businesses to compete for SBIR awards, according to a new Government Accountability Office study.
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association for life science and technology, today announced that it will honor former Lockheed Martin Corporation Chairman and CEO Norman Augustine, MedImmune, Inc. Founder Dr. Wayne Hockmeyer and University System of Maryland Chancellor William Kirwan with its 2015 Lifetime Achievement Awards. The awards will be presented during TCM’s Lifetime Achievement Gala, February 19, 2015.
